摘要
目的探讨肿瘤减灭术前及术后应用新辅助化疗治疗老年卵巢癌的效果。方法选择老年卵巢癌患者98例,按照交替分组法分为2组,其中A组49例接受肿瘤减灭术前应用新辅助化疗治疗,B组49例接受肿瘤减灭术后新辅助化疗治疗。观察2组治疗疗效,对比2组治疗前及完成治疗后血管内皮生长因子(VEGF)、血清人附睾上皮分泌蛋白4(HE4)及糖类抗原125(CA125)水平,记录2组理想减灭率、残余病灶直径及手术相关指标。治疗后对2组患者进行1年随访,统计1年生存情况。结果与B组相比,A组治疗总有效率高,差异有统计学意义(P<0.05)。2组治疗后血清VEGF、CA125及HE4水平均较治疗前低,且A组低于B组,差异有统计学意义(P<0.05)。A组手术时间短于B组,术中出血量及残余病灶直径小于B组,差异有统计学意义(P<0.05)。2组1年生存率对比差异无统计学意义(P>0.05);A组理想减灭率高于B组,差异有统计学意义(P<0.05)。结论与肿瘤减灭术后应用新辅助化疗治疗相比,于术前采用新辅助化疗治疗老年卵巢癌,疗效更佳,可提高肿瘤减灭率,缩短手术时间、减少术中出血量,且可降低肿瘤标志物水平。
Objective To investigate the effect of neoadjuvant chemotherapy in the treatment of elderly ovarian cancer before and after tumor reduction surgery.Methods 98 elderly patients with ovarian cancer were selected,they were divided into 2 groups according to the alternating grouping method,49 patients in group A was received neoadjuvant chemotherapy before tumor reduction surgery,49 patients in group B was received neoadjuvant chemotherapy after tumor reduction surgery.The therapeutic effects of the 2 groups were observed,the levels of vascular endothelial growth factor(VEGF),human epididymal epithelial secretory protein 4(HE4)and carbohydrate antigen 125(CA125)were compared between the 2 groups before and after treatment,the ideal reduction rate,residual lesion diameter and operation related indexes between the 2 groups were recorded,after treatment,patients in the 2 groups were followed up for 1 year,the survival condition of patients was counted within one year.Results Compared with group B,the total effective rate of group A was higher,with a statistical significant difference(P<0.05);after treatment,serum VEGF,CA125 and HE4 levels in the 2 groups were lower than those before treatment,and group A was lower than group B,with a statistical significant difference(P<0.05).the operation time of group A was shorter than group B,the intraoperative blood loss and the diameter of involved lesions were smaller than group B,with a statistical significant difference(P<0.05);compared the 1-year survival rate of the 2 groups,the difference was not statistically significant(P>0.05);the ideal extinction rate of group A was higher than group B,with a statistical significant difference(P<0.05).Conclusion Compared with the application of neoadjuvant chemotherapy after tumor reduction surgery,the application of neoadjuvant chemotherapy before tumor reduction surgery in the treatment of patients with ovarian cancer is more effective,it can improve the tumor reduction rate,shorten the operation time,reduce the intraoperative blood lo
作者
刘清
LIU Qing(Xinyang Central Hospital,Xinyang,464000)
出处
《实用癌症杂志》
2021年第9期1497-1499,1504,共4页
The Practical Journal of Cancer
关键词
卵巢癌
新辅助化疗
肿瘤减灭术
血管内皮生长因子
理想减灭率
Ovarian cancer
Neoadjuvant chemotherapy
Tumor reduction surgery
Vascular endothelial growth factor
Ideal reduction rate
